Durvalumab ± Tremelimumab + Chemotherapy in First-Line Metastatic NSCLC: 5-Year Overall Survival Update from the POSEIDON Study


In Partnership With:

Joshua K. Sabari, MD, reviews data from the 5-year overall survival update from the POSEIDON study investigating durvalumab, tremelimumab, and chemotherapy in first-line metastatic non–small cell lung cancer.


  • In the Phase 3 POSEIDON study, 1L treatment with tremelimumab + durvalumab + CT demonstrated statistically significant improvements in both PFS and OS vs CT alone in patients with mNSCLC
    • PFS HR 0.72 (95% CI 0.60–0.86; p=0.0003)*; OS HR 0.77 (95% CI 0.65–0.92; p=0.0030)
    • Based on these results, tremelimumab + durvalumab + CT was approved for 1L treatment of patients with mNSCLC
  • Durvalumab + CT significantly improved PFS vs CT, with a positive trend for OS improvement that did not reach statistical significance1
    • PFS HR 0.74 (95% CI 0.62–0.89; p=0.0009)*; OS HR 0.86 (95% CI 0.72–1.02; p=0.0758)
  • Long-term follow-up analyses of OS were prespecified
  • Here we report updated results after a median follow-up of >5 years‡, including analyses by histology (NSQ or SQ) and by STK11, KEAP1 or KRAS mutational status (m or wt)


  • Durvalumab 1500mg ± limited-course tremelimumab 75mg + CT q3w for 4 cycles
    • One additional dose of tremelimumab post-CT (week 16; 5th dose)
  • Followed by durvalumab q4w maintenance until PD, and optional pemetrexed q4w


  • Sustained OS benefit for T+D+CT vs CT with HR 0.76 and 5-yr OS rates more than twice as high (15.7% vs 6.8%)
  • Long-term OS benefit with T+D+CT vs CT more pronounced in NSQ with HR 0.69 and 5-yr OS rates 20.5% vs 9.1%
  • OS benefit maintained for T+D+CT vs CT in STK11m with HR 0.57 and 5-yr OS rates 12.9% vs 0%
  • OS benefit maintained for T+D+CT vs CT in KEAP1m with HR 0.43 (small sample size)
  • OS benefit maintained for T+D+CT vs CT in KRASm with HR 0.55 and 5-yr OS rates 21.7% vs 8.1%
  • SAEs, including AEs leading to death, were collected during long-term follow-up
    • No other safety data were collected after the final analysis for OS superiority
  • Since the final analysis‡, 7 additional patients experienced SAEs (including 1 considered treatment related) and 4 additional patients had AEs leading to death (none treatment related)


  • Prespecified updated analyses from POSEIDON after median follow-up of >5 years demonstrate the durable long-term OS benefit of adding a limited course of tremelimumab to durvalumab (until PD) and 4 cycles of CT
    • OS HR vs CT 0.76 (95% CI 0.64–0.89); 5-year OS rates more than twice as high (15.7% vs 6.8%)
    • No new safety signals were identified in the long-term follow-up of SAEs
  • Across patient subgroups, long-term OS benefit was generally consistent with the ITT population
    • Updated OS benefit with tremelimumab + durvalumab + CT vs CT continued to be more pronounced in patients with NSQ vs SQ histology
    • Consistent with earlier analyses,1,2 the addition of tremelimumab to durvalumab and CT provided OS benefit regardless of PD-L1 expression, including in patients with PD-L1 TC <1%
  • OS benefit was maintained with tremelimumab + durvalumab + CT vs CT in STK11m (NSQ), KEAP1m* or KRASm (NSQ) mNSCLC
    • Harder-to-treat mutational subgroups in mNSCLC will be further explored in the upcoming randomised Phase 3B TRITON study (NCT06008093)
  • These results support the use of tremelimumab + durvalumab + CT as a 1L treatment option for patients with mNSCLC, including in harder-to-treat subgroups

Peters S, Chul Cho B, Luft A et al. LBA3 – Durvalumab ± Tremelimumab + Chemotherapy in First-Line Metastatic NSCLC: 5-Year Overall Survival Update from the POSEIDON Study. Abstract presented at ESMO Immuno-Oncology Congress 2023, December 6-8, 2023.

Related Videos
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Saad J. Kenderian, MB, CHB
Jaime Schneider, MD, PhD
Benjamin Creelan, MD
Neel P. Chudgar, MD
Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine